SEARCH:   Advanced

Blood, 15 August 2007, Vol. 110, No. 4, pp. 1123-1131. Prepublished online as a Blood First Edition Paper on April 27, 2007; DOI 10.1182/blood-2006-12-063008. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-12-063008v1 110/4/1123    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Haque, T. Articles by Crawford, D. H. Search for Related Content PubMed PubMed Citation Articles by Haque, T. Articles by Crawford, D. H. Related Collections Neoplasia Immunotherapy Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial Tanzina Haque1, Gwen M. Wilkie1, Marie M. Jones1, Craig D. Higgins2, Gillian Urquhart1, Phoebe Wingate1, David Burns1, Karen McAulay1, Marc Turner3, Christopher Bellamy4, Peter L. Amlot5, Deirdre Kelly6, Alastair MacGilchrist7, Maher K. Gandhi8, Anthony J. Swerdlow2, and Dorothy H. Crawford1 1 Clinical and Molecular Virology Laboratory, University of Edinburgh, Edinburgh, United Kingdom; 2 Sir Richard Doll Building, Institute of Cancer Research, Sutton, United Kingdom; 3 Scottish National Blood Transfusion Service, Royal Infirmary, Edinburgh, United Kingdom; 4 Department of Pathology, Royal Infirmary, Edinburgh, United Kingdom; 5 Department of Immunology, Royal Free Hospital and University College Medical School, London, United Kingdom; 6 Liver Unit, Birmingham Children's Hospital, Birmingham, United Kingdom; 7 Liver Transplant Unit, Edinburgh Royal Infirmary, Edinburgh, United Kingdom, 8 Immunohaematology Laboratory, Queensland Institute of Medical Research, Brisbane, Australia We present the results of a multicenter clinical trial using Epstein-Barr virus (EBV)–specific cytotoxic T lymphocytes (CTLs) generated from EBV-seropositive blood donors to treat patients with EBV-positive posttransplantation lymphoproliferative disease (PTLD) on the basis of the best HLA match and specific in vitro cytotoxicity. Thirty-three PTLD patients who had failed on conventional therapy were enrolled. No adverse effects of CTL infusions were observed and the response rate (complete or partial) in 33 patients was 64% at 5 weeks and 52% at 6 months. Fourteen patients achieved a complete remission, 3 showed a partial response, and 16 had no response at 6 months (5 died before completing treatment). At 5 weeks, there was a significant trend toward better responses with higher numbers of CD4+ cells in infused CTL lines (P = .001) that were maintained at 6 months (P = .001). Patients receiving CTLs with closer HLA matching responded better at 6 months (P = .048). Female patients responded better than male patients, but the differences were not statistically significant. Our results show that allogeneic CTLs are a safe and rapid therapy for PTLD, bypassing the need to grow CTLs for individual patients. The response rate in this poor prognosis patient group is encouraging. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: EBV-specific T-cell therapy Lode J. Swinnen Blood 2007 110: 1087-1088. [Full Text] [PDF] This article has been cited by other articles: R. Zappasodi, M. Di Nicola, C. Carlo-Stella, R. Mortarini, A. Molla, C. Vegetti, S. Albani, A. Anichini, and A. M. Gianni The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells Haematologica, October 1, 2008; 93(10): 1523 - 1534. [Abstract] [Full Text] [PDF] M. L. Gulley and W. Tang Laboratory Assays for Epstein-Barr Virus-Related Disease J. Mol. Diagn., July 1, 2008; 10(4): 279 - 292. [Abstract] [Full Text] [PDF] D. Adhikary, U. Behrends, R. Feederle, H.-J. Delecluse, and J. Mautner Standardized and Highly Efficient Expansion of Epstein-Barr Virus-Specific CD4+ T Cells by Using Virus-Like Particles J. Virol., April 15, 2008; 82(8): 3903 - 3911. [Abstract] [Full Text] [PDF] H. Kobayashi, T. Nagato, M. Takahara, K. Sato, S. Kimura, N. Aoki, M. Azumi, M. Tateno, Y. Harabuchi, and E. Celis Induction of EBV-Latent Membrane Protein 1-Specific MHC Class II-Restricted T-Cell Responses against Natural Killer Lymphoma Cells Cancer Res., February 1, 2008; 68(3): 901 - 908. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020